Fo­s­un Phar­ma con­sid­ers $3.8B sale of In­di­an drug­mak­er Gland Phar­ma — re­port

The Fo­s­un Phar­ma­ceu­ti­cal Group may be con­sid­er­ing the sale of a com­pa­ny it took a stake in just a few years ago.

Ac­cord­ing to a re­port from Bloomberg News on Tues­day, Fo­s­un is con­sid­er­ing the sale of the In­di­an-based in­jectable CD­MO Gland Phar­ma Ltd. af­ter it had re­port­ed­ly re­ceived in­ter­est from po­ten­tial buy­ers.

Bloomberg said in its re­port that Fo­s­un has been work­ing with an ad­vis­er as it in­for­mal­ly “gauges in­ter­est” in its con­trol­ling stake in Gland. Oth­er com­pa­nies and buy­out firms are in the be­gin­ning stages of look­ing at Gland, but no de­tails have emerged on any po­ten­tial buy­ers, the re­port says. The pub­li­ca­tion lists the mar­ket val­ue of Gland at around $3.8 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.